Journals / Infectious diseases and clinical microbiology (Online) / 2021 / Cilt: 3 - Sayı: 3

Evaluation of Regulatory T Cells in Chronic Hepatitis C Patients

Pages
137–144
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Treg percentages of the subjects with hepatitis C infection (7.97±1.25) were significantly higher than those of the healthy control group (4.29±1.37) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Although there have been significant improvements in treatment strategies, hepatitis C infection is still among the most critical public health problems worldwide.
📊
Key Findings & Data:Materials and Methods: The peripheral blood samples were taken from sixty volunteers, including 30 non-cirrhotic chronic hepatitis C patients and 30 healthy controls selected from infectious diseases outpatient/clinic service applicants.
💡
Conclusion & Impact:Results: Treg percentages of the subjects with hepatitis C infection (7.97±1.25) were significantly higher than those of the healthy control group (4.29±1.37) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Although there have been significant improvements in treatment strategies, hepatitis C infection is still among the most critical public health problems worldwide. Upon entry of hepatitis C virus (HCV) into host liver cells, many antagonist immune responses are induced, including the production of regulatory T cells (Tregs). The main function of Tregs is coordinating an appropriate immune response, including suppression of this response once it is no longer needed. Tregs protect cells from immunopathologic damage of HCVspecific T cells but, on the other hand, cause viral persistence, cirrhosis and hepatocellular carcinoma (HCC). In this study, we aimed to determine whether the evaluation of Tregs in hepatitis C patients was a useful method for indicating disease chronicity. Materials and Methods: The peripheral blood samples were taken from sixty volunteers, including 30 non-cirrhotic chronic hepatitis C patients and 30 healthy controls selected from infectious diseases outpatient/clinic service applicants. Their CD4+CD25high FoxP3+CD152+CD127low Treg distributions were measured by flow cytometry, using recently identified markers combined. Results: Treg percentages of the subjects with hepatitis C infection (7.97±1.25) were significantly higher than those of the healthy control group (4.29±1.37) (p

🔖

Cite This Article

DEMİRDAL, T., KAYA, S., GÖKMEN, A. A., TOK, Y. T., ŞENER, A. G. (2022). Evaluation of Regulatory T Cells in Chronic Hepatitis C Patients. Infectious diseases and clinical microbiology (Online), Cilt: 3 - Sayı: 3, 137–144. https://ajindex.com/articles/539067

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. 1 Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Martinez-Lopez E, Roman S, Panduro A. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol. 2014
  2. 20(13):3443-56. [CrossRef] 2 Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015
  3. 61(1):77-87. [CrossRef] 3 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017
  4. 2(3):161- 76. [CrossRef] 4 Global Hepatitis Report, 2017 [Internet]. World Health Organization. (April 19, 2017
  5. cited July 28, 2021). Available from: https:// www.who.int/publications/i/item/global-hepatitis-report-2017 5 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018
  6. 69(2):461-511. [CrossRef] 6 Jung MK, Shin EC. Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw. 2016
  7. 16(6):330-6. [CrossRef] 7 Akiyama M, Ichikawa T, Miyaaki H, Motoyoshi Y, Takeshita S, Ozawa E, et al. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C. Intervirology. 2010
  8. 53(3):154-60. [CrossRef] 8 Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, et al. Circulating Tolllike receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS. 2010
  9. 118(4):261-70. [CrossRef] 9 Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat. 2009
  10. 16(12):844-52. [CrossRef] 10 Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond). 2010
  11. 119(2):97-109. [CrossRef] 11 Wan Z, Zhou Z, Liu Y, Lai Y, Luo Y, Peng X, et al. Regulatory T cells and T helper 17 cells in viral infection. Scand J Immunol. 2020
  12. 91(5):e12873. [CrossRef] 12 Garcia-Broncano P, Medrano LM, Berenguer J, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, et al. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status. Cells. 2018
  13. 7(11):196. [CrossRef] 13 Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+